Wednesday, 25 Apr 2018

You are here

RWCS Meeting Begins Today

The 11th annual meeting of the Rheumatology Winter Clinical Symposium (RWCS) begins today (2/7) and runs through Saturday (2/10) and features a premiere faculty delivering state-of-the-art lectures.

RheumNow will be covering this meeting with an active Twitter feed from @rheumnow and Dr. Rachel Tate (@uptotate). Video summaries from the faculty will be posted on RheumNow.com, YouTube and on the R-W-C-S.com websites. Lastly, watch for featured daily podcasts from each day’s presenters.

Lectures will include updates in rheumatoid arthritis, novel therapies, psoriatic arthritis, spondyloarthritis, dermatology, lupus, scleroderma and gout.  Novel lectures on telemedicine, biostatistics, outcome measures, pediatric rheumatology   emergency medicine and rheumatology. The RWCS teaching award recipient in 2018 is Dr. Bevra Hahn from UCLA who will lecture on " Accelerated athersosclerosis in rheumatic diseases" and "SLE: past, present, and future".

Other faculty for this program include Drs. Artie Kavanaugh, Eric Ruderman, Mark Genovese, Marty Bergman, Jack Cush, Orrin Troum, Alvin Wells, George Martin, Leslie Bilello, Anne Stevens and Uma Mahadevan.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.

RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory  SLE.

"Breakthrough" Drug Designation by the FDA

The current issue of the NEJM reviews the Food and Drug Administration (FDA) “breakthrough therapy” designation that was introduced in 2012 to expedite testing and approval of medications that were intended to treat serious or life-threatening conditions.  This status is granted when preliminary evidence with a new drug suggests substantial benefits over existing therapies for these unfortunate conditions.

ACR Projects Significant Manpower Shortages for 2030

Arthritis & Rheumatology has published the results of the 2015 Workforce Study of Rheumatology Specialists, and estimates a current shortage (demand > supply) of 700 (12.9%) full-time rheumatologists and that this deficit will worsen (102%) to 4133 FTE by 2030.

RheumNow Week in Review -The Temporal Artery Biopsy Letdown (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on the cost of RA care, infections on planes, CV events and Sacroiliitis in IBD, NXP-2 antibodies and calcinosis and rituximab in myositis ILD patients.